An Official Website of the United States Government
Malarial Vaccines Utilizing Antigen/Adjuvant Display on Viral-Like Particles
- Small Business Information
-
Woman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
- Phase 1
-
Fiscal Year: 2009Title: Malarial Vaccines Utilizing Antigen/Adjuvant Display on Viral-Like ParticlesAgency / Branch: DOD / ARMYContract: W81XWH-10-C-0005Award Amount: $70,000.00
Abstract:
Development of an effective malarial vaccine has been slow, although recent success in vaccine development has been achieved by using the Plasmodium falciparum circumsporozoite surface protein (CSP)-hepatitis B surface antigen fusions, in conjunction with hepatitis B particles (the RTS, S formulation). The results of these studies suggest the potential of improved malarial vaccines by use of the viral-like particle (VLP)-linked immunogen approach. The VLP technology is being utilized for the development of vaccines for a variety of diseases. Agave BioSystems proposes to develop a novel platform for development of malarial vaccines consisting of a VLP displayed malarial antigen/adjuvant based on the Norwalk virus (NV) capsid protein. The NV-VLP will be engineered to express a candidate antigen in combination with a peptide adjuvant. These VLPs will be characterized, purified and delivered for testing of efficacy to stimulate cellular and humoral immune responses.Small Business Information at Submission:AGAVE BIOSYSTEMS, INC.
P.O. Box 100 Ithaca, NY 14850EIN/Tax ID: 161551819DUNS: N/ANumber of Employees:Woman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
Award Information
|
Agency: Department of Defense |
Branch: Army |
Award ID: 92223 |
Program Year/Program: 2009 / SBIR |
|
Agency Tracking Number: A092-107-1383 |
Solicitation Year: N/A |
Solicitation Topic Code: N/A |
Solicitation Number: N/A |